September 22, 2017 Bio/Pharma/CRO Licensing, IP, and Legal

Roche receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer

Basel, 22 September 2017 Roche receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer TECENTRIQ provides a new treatment option for people with previously treated locally advanced or metastatic non-small cell cancer (NSCLC) TECENTRIQ is a new treatment option for people with metastatic... Read more

September 22, 2017 PR/Corporate

Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma

Basel, 22 September 2017 Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma Approval is based on phase III GALLIUM study results, which showed superior progression-free survival for Gazyva/Gazyvaro compared to MabThera/Rituxan Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Gazyvaro® (obinutuzumab) in combination... Read more

September 22, 2017 Bio/Pharma/CRO Licensing, IP, and Legal

Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma

Basel, 22 September 2017 Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma Approval is based on phase III GALLIUM study results, which showed superior progression-free survival for Gazyva/Gazyvaro compared to MabThera/Rituxan Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Gazyvaro® (obinutuzumab) in combination... Read more

September 18, 2017 Bio/Pharma/CRO PR/Corporate

Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan

Basel, 18 September 2017 Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan Data from pivotal phase III study will be submitted to health authorities and presented at an upcoming medical meeting Roche (SIX: RO, ROG; OTCQX:... Read more

September 18, 2017 Bio/Pharma/CRO PR/Corporate

Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan

Basel, 18 September 2017 Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan Data from pivotal phase III study will be submitted to health authorities and presented at an upcoming medical meeting Roche (SIX: RO, ROG; OTCQX:... Read more

September 15, 2017 Clinical Research/Diagn. Microscopy

TECENTRIQ GO29695 (NCT02431208) and BO29562 (NCT02631577) partial clinical hold reactive statement

Basel, 15 September 2017 TECENTRIQ GO29695 (NCT02431208) and BO29562 (NCT02631577) partial clinical hold reactive statement Roche (SIX: RO, ROG; OTCQX: RHHBY): Based on emerging safety data from clinical trials evaluating pembrolizumab in combination with either lenalidomide or pomalidomide in multiple myeloma, the FDA has requested that a Phase Ib and a Phase Ib/II TECENTRIQ study... Read more

September 13, 2017 Licensing, IP, and Legal PR/Corporate

Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS

Basel, 13 September 2017 Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS New study combining Esbriet (pirfenidone) and nintedanib showing similar safety profile for the combination treatment to that expected for each treatment alone A second, retrospective, post-hoc, analysis suggests that treatment with Esbriet may be... Read more

September 13, 2017 Licensing, IP, and Legal PR/Corporate

Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS

Basel, 13 September 2017 Results of a six-month study combining Roche’s Esbriet with nintedanib in patients with IPF presented at ERS New study combining Esbriet (pirfenidone) and nintedanib showing similar safety profile for the combination treatment to that expected for each treatment alone A second, retrospective, post-hoc, analysis suggests that treatment with Esbriet may be... Read more

September 11, 2017 Bio/Pharma/CRO

Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma

Basel, 11 September 2017 Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data for the phase III BRIM8 study, which was designed to investigate the efficacy and safety of Zelboraf® (vemurafenib) in the adjuvant (after surgery) treatment of people... Read more